MCI OneHealth, MDClone team up to use synthetic data to accelerate research

By Nick Taylor

- Last updated on GMT

(NatalyaBurova/iStock via Getty Images Plus)
(NatalyaBurova/iStock via Getty Images Plus)

Related tags Data management Clinical trials Research data analysis data analytics

The two companies are collaborating to generate subject data sets designed to help users find insights that can speed up research and improve patient care.

MCI OneHealth Partners has joined forces with MDClone to create synthetic, non-human subject data sets that accelerate research.

The companies are teaming up in the belief they have complementary capabilities. MCI OneHealth is a medical provider and custodian of healthcare data with real-world experience in specialized care delivery. MDClone is a platform provider with experience in data management and creating usable synthetic data sets for real-world evidence.

Josh Rubel, chief commercial officer, MDClone

By partnering, MCI OneHealth and MDClone will enable faster, more efficient access to real-world healthcare settings and data to review and find insights relevant to care delivery and new technology development. MCI’s collaboration with MDClone will provide our partners with greater access to data-insights-as-a-service and put the power of this expanded use of data in the hands of clinicians for an array of research, clinical, and data science needs​,” said Josh Rubel, chief commercial officer at MDClone.

MDClone will load, organize and protect MCI-generated patient data and use the data to find insights to improve care. The partners also plan to work together to improve data collection and curation to better serve the needs of applied healthcare research.

Rubel envisages the partnership accelerating insights and new technology by more closely connecting providers to innovators at the point of care and by creating synthetic, non-human subject data sets for model creation to prevent disease and/or slow disease progression.

This speeds the delivery of both data and research by circumventing cybersecurity/privacy risks and allows providers the opportunity to get their hands dirty with the data and research​,” said Rubel. “By making data less of a finite resource, this partnership will give researchers and clinicians an opportunity to spread their wings, ask questions, take a fresh perspective on transformation and search for insights and transformation in a way they previously could not​,” said Rubel.

News of the collaboration comes weeks after MDClone launched what it claims is the only synthetic data platform for life science real-world evidence project collaboration. The platform is designed to enable researchers to access, analyze and share information without privacy concerns that are unavoidable when working with actual, rather than synthetic, patient data.

Related news

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more